抗血管生成药物治疗肺癌脑转移的研究新进展

doi:10.11904/j.issn.1002-3070.2021.01.019

Abstract

Abstract: The incidence of brain metastases in advanced lung cancer is high and the prognosis is poor.In recent years,with the development of overall treatment for lung cancer,more treatments and expectations have been provided for advanced lung cancer with brain metastases.Current clinical studies suggest that antiangiogenic drugs play an important role in the treatment of lung cancer with brain metastasis including from monoclonal antibody to multi-target antiangiogenic drugs and then to small molecule tyrosine kinase inhibitor(TKI).These drugs have shown a certain efficacy and good safety,and they also show a significantly synergistic anti-tumor effect on chemotherapy,radiotherapy and epidermal growth factor receptor TKI(EGFR-TKI).This article reviews the new progress of anti-angiogenic drugs in the treatment of lung cancer with brain metastases.

Key words: Antiangiogenesis, Lung cancer, Brain metastases

CLC Number:

R734.2

BAO Yu,ZHU Lijian,QIAN Jiang. New progress in the research of anti-angiogenic drugs in the treatment of lung cancer with brain metastases[J]. Journal of Practical Oncology, 2021, 35(1): 91-96.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2021.01.019

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2021/V35/I1/91

References

1 Villano JL,Durbin EB,Normandeau C,et al.Incidence of brain metastasis at initial presentation of lung cancer[J].Neuro Oncol,2015,17(1):122-128.
2 Goncalves PH,Peterson SL,Vigneau FD,et al.Risk of brain metastases in patients with nonmetastatic lung cancer:analysis of the Metropolitan Detroit Surveillance,Epidemiology,and End Results(SEER)data[J].Cancer,2016,122(12):1921-1927.
3 中国临床肿瘤学会,中国抗癌协会肺癌专业委员会.肺癌脑(膜)转移诊断治疗共识[J].循证医学,2018,18(4):193-201.
4 代欣,张大昕.非小细胞肺癌抗血管生成治疗研究现状[J].实用肿瘤学杂志,2017,31(5):472-475.
5 杨珑静,马洪波,张献全,等.抗血管生成药物在非小细胞肺癌中的应用及研究进展[J].医学信息,2019,32(8):58-66.
6 Hanibuchi M,Kim SJ,Fidler IJ,et al.The molecular biology of lung cancer brain metastasis:an overview of current comprehensions and future perspectives[J].J Med Invest,2014,61(3/4):241-253.
7 Lee SH,Jeong D,Han YS,et al.Pivotal role of vascular endothelial growth factor pathway in tumor angiogenesis[J].Ann Surg Treat Res,2015,89(1):1-8.
8 Sandler A,Gray R,Perry MC,et al.Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer[J].N Engl J Med,2006,355(24):2542-2550.
9 Reck M,von Pawel J,Zatloukal P,et al.Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer:AVAil[J].J Clin Oncol,2009,27(8):1227-1234.
10 Zhou C,Wu YL,Chen G,et al.BEYOND:a randomized,double-blind,placebo-controlled,multicenter,phase III study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in Chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer[J].J Clin Oncol,2015,33(19):2197-2204.
11 Besse B,Lasserre SF,Compton P,et al.Bevacizumab safety in patients with central nervous system metastases[J].Clin Cancer Res,2010,16(1):269-278.
12 Besse B,Le Moulec S,Mazières J,et al.Bevacizumab in patients with nonsquamous non-small cell lung cancer and asymptomatic,untreated brain metastases(BRAIN):a nonrandomized,phase II study[J].Clin Cancer Res,2015,21(8):1896-1903.
13 Stefanou D,Stamatopoulou S,Sakellaropoulou A,et al.Bevacizumab,pemetrexed and carboplatin in first-line treatment of non-small cell lung cancer patients:focus on patients with brain metastases[J].Oncol Lett,2016,12(6):4635-4642.
14 Tian Y,Zhai X,Tian H,et al.Bevacizumab in combination with pemetrexed and platinum significantly improved the clinical outcome of patients with advanced adenocarcinoma NSCLC and brain metastases[J].Cancer Manag Res,2019,11:10083-10092.
15 Gubens MA,Chuang JC,Akerley W,et al.A pooled analysis of advanced nonsquamous non-small cell lung cancer patients with stable treated brain metastases in two phase II trials receiving bevacizumab and pemetrexed as second-line therapy[J].J Thorac Dis,2018,10(1):219-227.
16 Wang Z,Yang JJ,Tu HY,et al.Retrospective study on bevacizumab in the treatment of non-small cell lung cancer with brain metastases[J].Int J Clin Oncol,2019,25(2):267-273.
17 Chikaishi Y,Kanayama M,Taira A,et al.Effect of erlotinib plus bevacizumab on brain metastases in patients with non-small cell lung cancer[J].Ann Transl Med,2018,6(20):401-407.
18 Yang RF,Yu B,Zhang RQ,et al.Bevacizumab and gefitinib enhanced whole-brain radiation therapy for brain metastases due to non-small cell lung cancer[J].Braz J Med Biol Res,2017,51(1):6073-6081.
19 Jiang T,Zhang Y,Li X,et al.EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in patients with EGFR-mutant NSCLC and multiple brain metastases[J].Eur J Cancer,2019,121:98-108.
20 Lévy C,Allouache D,Lacroix J,et al.REBECA:a phase I study of bevacizumab and whole-brain radiation therapy for the treatment of brain m etastasis from solid tumours[J].Ann Oncol,2014,25(12):2351-2357.
21 潘绵顺,李勇,邱书珺,等.SRT联合贝伐珠单抗治疗肺腺癌脑转移瘤的疗效评估[J].中华放射肿瘤学杂志,2017,26(8):880-883.
22 Uprety D.Clinical utility of ramucirumab in non-small cell lung cancer[J].Biologics,2019,13:133-137.
23 Tanimura K,Uchino J,Tamiya N,et al.Treatment rationale and design of the RAMNITA study[J].Medicine,2018,97(23):e11084.
24 王金万,孙燕,刘永煜,等.重组人血管内皮抑素联合NP方案治疗晚期NSCLC随机、双盲、对照、多中心Ⅲ期临床研究[J].中国肺癌杂志,2005,8(4):283-290.
25 吴竞,樊锐太,王鑫,等.重组人血管内皮抑素联合放化疗治疗非小细胞肺癌脑转移[J].河南医学研究,2014,23(1):51-53.
26 Jiang X,Ding M,Qiao Y,et al.Recombinant human endostatin combined with radiotherapy in the treatment of brain metastases of non-small cell lung cancer[J].Clin Transl Oncol,2014,16(7):630-636.
27 Knisely JP,Berkey B,Chakravarti A,et al.A phase III study of conventional radiation therapy plus thalidomide versus conventional radiation therapy for multiple brain metastases(RTOG 0118)[J].Int J Radiat Oncol Biol Phys,2008,71(1):79-86.
28 刘建刚,施朕善,徐珊珊,等.沙利度胺联合放疗治疗晚期非小细胞肺癌脑转移临床疗效观察[J].临床肺科杂志,2018,23(6):1010-1012.
29 Lee SM,Rudd R,Woll PJ,et al.Randomized double-blind placebo-controlled trial of thalidomide in combination with gemcitabine and carboplatin in advanced non-small-cell lung cancer[J].J Clin Oncol,2009,27(31):5248-5254.
30 Liu Y,He S,Ding Y,et al.The efficacy and safety of thalidomide-based therapy in patients with advanced non-small cell lung cancer:a meta-analysis[J].Contemp Oncol(Pozn),2014,18(1):39-47.
31 Wu F,Zhang S,Xiong A,et al.A phase II clinical trial of apatinib in pretreated advanced non-squamous non-small cell Lung Cancer[J].Clin Lung Cancer,2018,19(6):831-842.
32 Yu GC,Yang J,Ye B,et al.Apatinib in the treatment of advanced non-small-cell lung cancer:A meta-analysis[J].Math Biosci Eng,2019,16(6):7659-7670.
33 Leng J,Li DR,Huang LM,et al.Apatinib is effective as third-line and more treatment of advanced metastatic non-small-cell lung cancer:a retrospective analysis in a real-world setting[J].Medicine(Baltimore),2019,98(36):16967-1683.
34 张智显,顾后,林劼,等.伽玛刀联合阿帕替尼及替莫唑胺治疗肺癌脑转移的疗效[J].昆明医科大学学报,2018,39(12):65-68.
35 张智显,顾后,林劫,等.阿帕替尼联合替莫唑安序贯全脑放疗二线治疗小细胞肺癌脑转移[J].昆明医科大学学报,2019,40(8):97-101.
36 Xu J,Liu X,Yang S,et al.Apatinib monotherapy or combination therapy for non-small cell lung cancer patients with brain metastases[J].Oncol Res,2020,28(2):127-133.
37 Han B,Li K,Wang Q,et al.Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer:the ALTER 0303 Phase 3 randomized clinical trial[J].JAMA Oncol,2018,4(11):1569-1575.
38 Jiang S,Liang H,Liu Z,et al.The impact of anlotinib on brain metastases of non-small cell lung cancer:post hoc analysis of a phase III randomized control trial(ALTER0303)[J].Oncologis,2020[Epub ahead of print].
39 黄行志,蔡凡,刘高,等.安罗替尼联合放疗治疗非小细胞肺癌伴脑转移的临床分析[J].基层医学论坛,2020,24(1):5-7.
40 Wang Y,Wang X,Guan Y,et al.Stereotactic radiosurgery combined with anlotinib for limited brain metastases with perilesional edema in non-small cell lung cancer:Rvision-001 study protocol[J].Thorac Cancer,2020,11(5):1361-1364.
41 Paz-Ares L,Hirsh V,Zhang L,et al.Monotherapy administration of sorafenib in patients with non-small cell lung cancer(MISSION)trial:a phase III,multicenter,placebo-controlled trial of sorafenib in patients with relapsed or refractory predominantly non-squamous non-small cell lung cancer after 2 or 3 previous treatment regimens[J].J Thorac Oncol,2015,10(12):1745-1753.
42 Laurie SA,Solomon BJ,Seymour L,et al.Randomised,double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer:NCIC Clinical Trials Group study BR29[J].Eur J Cancer,2014,50(4):706-712.
43 Yoh K,Seto T,Satouchi M,et al.Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer(LURET):an open-label,multicentre phase 2 trial[J].Lancet Respir Med,2017,5(1):42-50.
44 Yoh K,Seto T,Satouchi M,et al.LURET:final survival results of the phase II trial of vandetanib in patients with advanced RET-rearranged non-small cell lung cancer[J].Ann Oncol,2018,29(Suppl 8):538.
45 Subbiah V,Berry J,Roxas M,et al.Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases[J].Lung Cancer,2015,89(1):76-79.
46 Capelletto E,Migliorino MR,Morabito A,et al.Final results of the SENECA(second line nintedanib in non-small cell lung cancer)trial[J].Lung Cancer,2019,134:210-217.
47 Lu S,Chang J,Liu X,et al.Randomized,double-blind,placebo-controlled,multicenter phase II study of fruquintinib after two prior chemotherapy regimens in Chinese patients with advanced non-squamous non-small cell lung cancer[J].J Clin Oncol,2018,36(12):1207-1217.
48 Yao Y,Zhou Y,Hua Q.Comparing efficacy and safety of regorafenib versus pemetrexed in lung cancer:a preliminary clinical trial evaluating effect of inflammatory biomarkers on disease progression[J].Pak J Pharm Sci,2019,32(3 Special):1293-1299.

[1]	DONG Cheng,DUAN Yong. Research progress on the mechanism and treatment of Dickkopf family protein in non-small cell lung cancer [J]. Journal of Practical Oncology, 2021, 35(1): 64-68.
[2]	YAN Yan, HOU Lifang, LI Renfei, YAN Peng, WANG Yuedong, ZHENG Yuting. Imaging with ^99mTc-HYNIC-MPG molecular typing of non-small cell lung cancer in vivo [J]. Journal of Practical Oncology, 2020, 34(5): 412-417.
[3]	CHENG Yue, ZHANG Mingyan, ZHANG Wenbo, XU Hui. Research progress of lncRNAs as members of ceRNAs networks in lung cancer [J]. Journal of Practical Oncology, 2020, 34(5): 451-455.
[4]	ZHAO Rencheng, LIN Zitang, YU Weijun, LEI Lin, LIU Zheng, XU Ying, GUO Yanfang, PENG Ji. Analysis of the prevalence of five cancer risks among permanent residents aged 40~74 years old in Baoan District,Shenzhen,2017—2019 [J]. Journal of Practical Oncology, 2020, 34(4): 315-320.
[5]	MENG Ruirui, LIU Yuanyuan, GUAN Xinli, ZHOU Peng, XU Guohui. Status and progress of low-dose spiral CT in lung cancer screening [J]. Journal of Practical Oncology, 2020, 34(4): 372-376.
[6]	CHEN Lantao, YAN We, LIU Jinglei, YAO Lei. Effect of tetrandrine on lung cancer H1299 cells and A549 cells and its molecular mechanism [J]. Journal of Practical Oncology, 2020, 34(2): 126-132.
[7]	ZHU Yucheng, SUN Xin, MENG Dan. The effect of ketorolac tromethamine on preventive analgesia in the immune function of patients with lung cancer surgery [J]. Journal of Practical Oncology, 2020, 34(2): 176-180.
[8]	FAN Pangshuang, PANG Xianqiong. The mechanism of miR-616 enhancing the radiosensitivity of lung cancer cells by targeting TIMP-2 [J]. Journal of Practical Oncology, 2020, 34(1): 30-36.
[9]	NIE Jian, CHEN Gongyan. Clinical and prognostic value of coagulation parameters in small cell lung cancer: A retrospective study [J]. Journal of Practical Oncology, 2020, 34(1): 49-54.
[10]	SUN Yipeng, NI Zhenhua, WU Yingying, CHEN Qingge, BI Junjie, LIN Yuhua, WANG Xiongbiao. Overexpression of CLPTM1L inhibits the sensitivity of 95-D lung cancer cells to gemcitabine [J]. Journal of Practical Oncology, 2019, 33(6): 486-490.
[11]	LI Chuanhai, LIU Yu, WANG Yanqun, CHEN Yingjian. The role and mechanism of ABL2 in lung cancer [J]. Journal of Practical Oncology, 2019, 33(6): 497-501.
[12]	LI Jian, XU Xiangying, LV Yan. Correlation study of recurrent treatment after limited first-course treatment of small cell lung cancer [J]. Journal of Practical Oncology, 2019, 33(6): 519-524.
[13]	WANG Jingxi, DONG Xiaoping, ZHANG Xue, HE Yutong. Research progress of MiR-26a in lung cancer [J]. Journal of Practical Oncology, 2019, 33(6): 561-565.
[14]	SUN Yajuan, JIANG Zhiyun, SHANG Naijian, SUN Qingxin, LU Peiou. Value of dual-source CT energy imaging in evaluating mediastinal lymph node metastasis in non-small cell lung cancer [J]. Journal of Practical Oncology, 2019, 33(6): 531-535.
[15]	LIU Siwei, CUI Yue, SUN Yuanyuan, HU Jing, ZHANG Wenrui, CAO Mengru. Effect of FOXD3 in lung cancer cells [J]. Journal of Practical Oncology, 2019, 33(5): 390-396.

New progress in the research of anti-angiogenic drugs in the treatment of lung cancer with brain metastases

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments